pubmed.ncbi.nlm.nih.gov

Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies - PubMed

Review

Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies

Bindiya Thakkar et al. Metabolism. 2013 Jul.

Abstract

Introduction: Accumulating evidence suggests that patients with type 2 diabetes mellitus (T2DM) and hyperinsulinemia are at increased risk for developing malignancies. It remains to be fully elucidated whether use of metformin, an insulin sensitizer, and/or sulfonylureas, insulin secretagogues, affect cancer incidence in subjects with T2DM.

Material & methods: We performed a meta-analysis using PubMed, of randomized control trials (RCTs), cohorts, and case-control studies published through July 2012 that assess effects of metformin and/or sulfonylurea sulfonylureas on cancer risk at any site, in subjects with T2DM. Fixed and random effects meta-analysis models were used, and the effect size was summarized as relative risk (RR) for RCTs/cohorts and as odds ratio (OR) for the case-control studies.

Results: Analysis of 24 metformin studies in subjects with T2DM showed that metformin use is associated with reduced risk for the development of cancer, in both cohort (RR=0.70 [95% CI=0.67-0.73]) and case-control studies (OR=0.90 [95% CI=0.84-0.98]), but this finding was not supported by RCTs (RR=1.01[95% CI=0.81-1.26]). Data from 18 sulfonylurea studies in subjects with T2DM showed that sulfonylurea use is associated with an increase in all-cancer risk, in cohort studies (RR=1.55 [95% CI=1.48 -1.63]), though data from RCTs (RR=1.17 [95% CI=0.95-1.45]) and case-control studies (OR=1.02 [95% CI=0.93-1.13]) failed to demonstrate a statistically significant effect.

Conclusions: This analysis using pooled primary data demonstrates that metformin use reduces, while sulfonylurea use may be associated with an increased cancer risk in subjects with T2DM. These findings need to be confirmed in large-scale RCTs before they are translated into clinical practice.

Published by Elsevier Inc.

PubMed Disclaimer

Cited by

Systematic review of antitumour efficacy and mechanism of metformin activity in prostate cancer models.
Wang NF, Jue TR, Holst J, Gunter JH. Wang NF, et al. BJUI Compass. 2022 Sep 30;4(1):44-58. doi: 10.1002/bco2.187. eCollection 2023 Jan. BJUI Compass. 2022. PMID: 36569495 Free PMC article. Review.
The Relationship between Metformin Consumption and Cancer Risk: An Updated Umbrella Review of Systematic Reviews and Meta-Analyses.
Najafi F, Rajati F, Sarokhani D, Bavandpour M, Moradinazar M. Najafi F, et al. Int J Prev Med. 2023 Jul 15;14:90. doi: 10.4103/ijpvm.ijpvm_62_21. eCollection 2023. Int J Prev Med. 2023. PMID: 37854987 Free PMC article. Review.
Associations between Diabetes Mellitus and Selected Cancers.
Pliszka M, Szablewski L. Pliszka M, et al. Int J Mol Sci. 2024 Jul 8;25(13):7476. doi: 10.3390/ijms25137476. Int J Mol Sci. 2024. PMID: 39000583 Free PMC article. Review.
Past, Present, and Future Research Avenues for Metformin: A Literature Review.
Sparkes ST, Patel DK, Goldman-Levine JD. Sparkes ST, et al. J Pharm Technol. 2014 Dec;30(6):227-234. doi: 10.1177/8755122514544527. Epub 2014 Jul 24. J Pharm Technol. 2014. PMID: 34860874 Free PMC article.
Repurposing metformin: an old drug with new tricks in its binding pockets.
Pryor R, Cabreiro F. Pryor R, et al. Biochem J. 2015 Nov 1;471(3):307-22. doi: 10.1042/BJ20150497. Biochem J. 2015. PMID: 26475449 Free PMC article. Review.

Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies - PubMed